Our Portfolio 

Our portfolio reflects the scale and diversity of the broader healthcare venture capital market.


For over 13 years, we have created customized solutions for venture funds, corporate venture funds, limited partnership interests, operating companies, and individual shareholders.

hotspot therapeutics logo_colour_master_rgb.png

HotSpot Therapeutics is inspired by nature and leading a paradigm shift in drug discovery by unlocking the on/off switches on proteins called “natural hotspots.”


23andMe was founded in 2006 to help people access, understand and benefit from the human genome. 

Prolacta logo_full-color.png

As a pioneer in human milk-based nutritional products, Prolacta produces specialty nutritional formulations made exclusively from human milk for critically ill premature infants in the NICU.


Carrick Therapeutics is building an innovative portfolio of first-in-class treatments that target multiple mechanisms of the most aggressive forms of cancer.


MISSION Therapeutics offers a platform for the development of small molecule drugs that selectively target deubiquitylating enzymes (DUBs).


The World Leading Cancer Gene Therapy Company.


Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases.


ReNeuron focuses on the development of stem-cell therapies targeting areas of poorly-met medical need, including peripheral arterial disease, strokes, and retinal diseases.


From mineral sunscreen to clinical skincare products, Colorescience utilizes potent, clinically-tested ingredients to maximize results for long-term skin health.


NewBridge focuses on in-licensing and commercializing approved innovative pharmaceutics, biologics, and other healthcare solutions into the Middle East and Africa regions.


Immunocore researches and develops biological drugs to treat cancer, infectious diseases and autoimmune diseases using soluble T-cell receptor technology.


Leading CRAC channel platform company delivering drug candidates for inflammatory diseases.


TheraVida is dedicated to the development of new therapies to improve the lives of patients with hyperhidrosis.